和厚朴酚增加CD4+ T细胞活化并降低TNF,但未能改善脓毒症生存
本研究采用盲肠结扎穿刺诱导的多微生物腹腔脓毒症小鼠模型,随机给予和厚朴酚(120 mg/kg/天)或溶媒注射,24小时后进行功能研究或随访7天生存。和厚朴酚治疗后脓毒症小鼠CD4+ T细胞频率增加、活化标志物CD69表达增加,脾脏树突状细胞增加,同时CD8+ T细胞频率和数量减少,全身肿瘤坏死因子降低而未影响其他全身细胞因子。和厚朴酚对肾功能、肺生理、肝功能或肠道完整性无可检测的影响。与既往在快速100%致死性脓毒症模型中的研究相反,和厚朴酚未改变7天生存率(和厚朴酚组死亡率70% vs 溶媒组60%)。作者结论认为和厚朴酚能有效调节临床相关脓毒症模型后的宿主免疫反应和炎症,但不足以改变生存。
要点
- 在盲肠结扎穿刺脓毒症小鼠中,和厚朴酚120 mg/kg/天治疗未改善7天生存:和厚朴酚组死亡率70% vs 溶媒组60%。
- 和厚朴酚增加脓毒症后CD4+ T细胞频率及CD69活化标志物表达,并增加脾脏树突状细胞。
- 和厚朴酚降低全身肿瘤坏死因子,未影响其他全身细胞因子,同时减少CD8+ T细胞频率和数量。
- 和厚朴酚对肾功能、肺生理、肝功能或肠道完整性无可检测的影响。
- 作者认为和厚朴酚能调节宿主免疫反应和炎症,但不足以改变生存。
适用人群与场景
- 雄性及雌性C57BL/6小鼠,行盲肠结扎穿刺诱导多微生物腹腔脓毒症。
处置流程与药物剂量
- 小鼠脓毒症后随机接受和厚朴酚120 mg/kg/天或溶媒注射;24小时后处死进行功能研究或随访7天生存。
研究设计与关键结果
- 研究类型:动物实验(小鼠盲肠结扎穿刺脓毒症模型);样本量原文未报告。
- 和厚朴酚增加CD4+ T细胞频率及CD69活化标志物表达,增加脾脏树突状细胞,减少CD8+ T细胞频率和数量。
- 和厚朴酚降低全身肿瘤坏死因子,未影响其他全身细胞因子;对肾功能、肺生理、肝功能或肠道完整性无可检测的影响。
- 和厚朴酚未改变7天生存:和厚朴酚组死亡率70% vs 溶媒组60%。
证据类型、等级与局限
- 证据类型:动物实验(小鼠脓毒症模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为和厚朴酚能有效调节临床相关脓毒症模型后的宿主免疫反应和炎症,但不足以改变生存。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Honokiol is a biphenolic isolate extracted from the bark of the magnolia tree that has been used in traditional Chinese and Japanese medicine, and has more recently been investigated for its anti-inflammatory and antibacterial properties. Honokiol has previously been demonstrated to improve survival in sepsis models that have rapid 100% lethality. The purpose of this study was to determine the impact of Honokiol on the host response in a model of sepsis that more closely approximates human disease. Male and female C57BL/6 mice underwent cecal ligation and puncture to induce polymicrobial intra-abdominal sepsis. Mice were then randomized to receive an injection of either Honokiol (120 mg/kg/day) or vehicle and were sacrificed after 24 h for functional studies or followed 7 days for survival. Honokiol treatment after sepsis increased the frequency of CD4 T cells and increased activation of CD4 T cells as measured by the activation marker CD69. Honokiol also increased splenic dendritic cells. Honokiol simultaneously decreased frequency and number of CD8 T cells. Honokiol decreased systemic tumor necrosis factor without impacting other systemic cytokines. Honokiol did not have a detectable effect on kidney function, lung physiology, liver function, or intestinal integrity. In contrast to prior studies of Honokiol in a lethal model of sepsis, Honokiol did not alter survival at 7 days (70% mortality for Honokiol vs. 60% mortality for vehicle). Honokiol is thus effective in modulating the host immune response and inflammation following a clinically relevant model of sepsis but is not sufficient to alter survival.
参考来源
- Klingensmith NJ, Chen CW, Liang Z, et al. Honokiol Increases CD4+ T Cell Activation and Decreases TNF but Fails to Improve Survival Following Sepsis. Shock. 2018. PMID: 29023360. doi:10.1097/SHK.0000000000001021
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。